Healthcare Services

Myocardial Ischemia Market Size Outlook and Demand Growth Across 2026–2030

April 2, 2026April 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Myocardial Ischemia Market In 2026 And What Value Is Projected For 2030?

The myocardial ischemia market size has experienced significant expansion in recent years. It is anticipated to expand from $0.84 billion in 2025 to attain $0.9 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 6.8%. This historical growth can be ascribed to an increase in coronary artery disease cases, a scarcity of early screening programs, the growing prevalence of hypertension, a reliance on conventional diagnostic methods, and lifestyle-related risk factors.

The myocardial ischemia market size is projected to experience robust expansion over the coming years. This market is set to reach $1.14 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.1%. The anticipated growth during this period is driven by advancements in imaging technologies, the increasing embrace of precision medicine, the broadening of preventive cardiology initiatives, heightened investment in cardiac research and development, and a surging demand for less invasive treatments. Key trends expected in the forecast period encompass the wider implementation of sophisticated cardiac imaging technologies, an escalating preference for minimally invasive cardiac interventions, a rise in the application of combination drug therapies, an intensified emphasis on preventive cardiology and early risk assessment, and a significant need for tailored cardiac treatment strategies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16488&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Myocardial Ischemia Market?

The increasing occurrence of diabetes is projected to fuel the expansion of the myocardial ischemia market in the future. Diabetes encompasses a set of metabolic conditions where the body struggles to produce or efficiently utilize insulin, a pancreatic hormone crucial for regulating blood sugar. This surge in diabetes cases stems from factors like obesity, severe obesity, insufficient physical activity, and genetic predispositions. The expanding prevalence of diabetes, in turn, contributes to a greater frequency of myocardial ischemia, thereby boosting the need for diagnostic tools, treatments, and management strategies for myocardial ischemia. For example, a report from The British Diabetic Association, a UK-based diabetes charity, indicated in April 2023 that 4.3 million individuals in the UK had been diagnosed with diabetes. Furthermore, registration figures for 2021-22 demonstrated an uptick of 148,951 cases compared to 2020-21. Additionally, more than 2.4 million people in the UK face a high risk of developing type 2 diabetes. Consequently, the escalating incidence of diabetes is propelling the growth of the myocardial ischemia market.

What Are The Key Segments Of The Myocardial Ischemia Market?

The myocardial ischemia market covered in this report is segmented –

1) By Type: Symptomatic, Asymptomatic

2) By Treatment And Diagnosis: Diagnosis, Treatment

3) By End User: Hospitals And Clinics, Diagnostic Centers, Ambulatory Surgery Centers

Subsegments:

1) By Symptomatic: Acute Myocardial Ischemia, Chronic Myocardial Ischemia, Stable Angina, Unstable Angina

2) By Asymptomatic: Silent Myocardial Ischemia, Exercise-Induced Asymptomatic Ischemia

What Trends Are Advancing Progress In The Myocardial Ischemia Market?

Leading companies within the myocardial ischemia market are developing innovative drugs, such as Lodoco (colchicine), designed to alleviate inflammation and decrease the likelihood of cardiovascular events in patients with coronary artery disease. Lodoco is recommended for reducing the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or multiple risk factors for cardiovascular disease. For example, in June 2023, Agepha Pharma, a US-based pharmaceutical company, introduced Lodoco (colchicine) after receiving approval from the Food and Drug Administration, a US-based government agency. This marks the first FDA-approved treatment specifically targeting cardiovascular inflammation. Its foundation comes from data gathered during the LoDoCo2 trial, which revealed a 31% relative reduction in the risk of cardiovascular events when colchicine 0.5 mg was taken once daily compared to a placebo. Lodoco is administered to diminish the chances of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death among adult patients with existing atherosclerotic disease or several cardiovascular risk factors.

Who Are The Leading Companies Operating In The Myocardial Ischemia Market?

Major companies operating in the myocardial ischemia market are Cardinal Health Inc., Pfizer Inc., Roche Holding AG, Bayer AG, Sanofi SA, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories Inc., Eli Lilly and Company, Medtronic Plc, Boehringer Ingelheim International GmbH, Siemens Healthineers AG, Merck KGaA, GE HealthCare Technologies Inc., Fujifilm Holdings Corporation, Boston Scientific Corporation, Daiichi Sankyo Company Limited, Canon Medical Systems Corporation, Johnson & Johnson, Koninklijke Philips NV, Biotronik SE & Co KG, Edwards Lifesciences Corporation, Teva Pharmaceutical Industries Ltd, Schiller AG, AliveCor Inc.

Read the full myocardial ischemia market report here:

https://www.thebusinessresearchcompany.com/report/myocardial-ischemia-global-market-report

What Are The Leading Geographic Regions In The Myocardial Ischemia Market?

North America was the largest region in the myocardial ischemia market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the myocardial ischemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Myocardial Ischemia Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16488&type=smp

Browse Through More Reports Similar to the Global Myocardial Ischemia Market 2026, By The Business Research Company

Myocardial Ischemia Global Market Report

https://www.thebusinessresearchcompany.com/report/myocardial-ischemia-global-market-report

Coronary Artery Disease Global Market Report

https://www.thebusinessresearchcompany.com/report/coronary-artery-disease-global-market-report

Acute Coronary Syndrome Global Market Report

https://www.thebusinessresearchcompany.com/report/acute-coronary-syndrome-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795